Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Characteristics of Most Important Gram-Negative Bacteria
Table 3: Prevalence of Antibiotic Resistance in Gram-Negative Bacteria Throughout the 7MM
Table 4: Symptoms of HAIs Caused by Gram-Negative Bacteria
Table 5: Risk Factors for Diagnosed Incident Cases of HAIs
Table 6: 7MM, Suspected Incident Cases of Select HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026
Table 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026
Table 8: National and International Treatment Guidelines for HAIs
Table 9: HAI Disease Management, Country Profile – US
Table 10: HAI Disease Management, Region Profile – 5EU
Table 11: HAI Disease Management, Region Profile – Japan
Table 12: Common Susceptibility Patterns in Gram-Negative Bacteria Isolated From the General Hospital Setting (non-ICU) and ICUs
Table 13: Leading Branded Treatments for HAI, 2016
Table 14: SWOT Analysis of Main Antibiotic Classes for HAIs Caused by Gram-Negative Bacteria
Table 15: Product Profile – Avycaz
Table 16: Efficacy of Avycaz in Patients with cIAIs
Table 17: Efficacy of Avycaz in Patients with cUTIs
Table 18: Safety of Avycaz
Table 19: Product Profile – Zerbaxa
Table 20: Efficacy of Zerbaxa in Patients with cIAIs
Table 21: Efficacy of Zerbaxa in Patients with cUTIs
Table 22: Safety of Zerbaxa
Table 23: Product Profile – Piperacillin/tazobactam
Table 24: Efficacy of Piperacillin/tazobactam in Patients with cIAIs
Table 25: Efficacy of Piperacillin/tazobactam in Patients with HAP
Table 26: Efficacy of Piperacillin/tazobactam in Patients with cUTIs
Table 27: Safety of Piperacillin/Tazobactam
Table 28: Product Profile – Ticarcillin/clavulanate
Table 29: Efficacy of Ticarcillin/clavulanate in Patients with cIAIs1
Table 30: Product Profile – Aztreonam
Table 31: Efficacy of Aztreonam
Table 32: Safety of Aztreonam in Patients with Bacterial Infections
Table 33: Product Profile – Doribax
Table 34: Efficacy of Doribax in Patients with cIAIs
Table 35: Efficacy of Doribax in Patients with cUTIs
Table 36: Safety of Doribax
Table 37: Product Profile – Invanz
Table 38: Efficacy of Invanz in Patients with cIAIs
Table 39: Efficacy of Invanz in Patients with cUTIs
Table 40: Safety of Invanz
Table 41: Most Frequently Used Cephalosporins in HAIs
Table 42: Product Profile – Levofloxacin
Table 43: Efficacy of Levaquin in Patients with Nosocomial Pneumonia
Table 44: Efficacy of Levaquin in Patients with cUTIs and Acute Pyelonephritis
Table 45: Safety of Levofloxacin in Patients with Bacterial Infections
Table 46: Product Profile – Ciprofloxacin
Table 47: Efficacy of Ciprofloxacin in Patients with cUTIs
Table 48: Safety of Ciprofloxacin in Patients with Bacterial Infections
Table 49: Product Profile – Moxifloxacin
Table 50: Efficacy of Moxifloxacin in Patients with cIAIs
Table 51: Safety of Moxifloxacin in Patients with Bacterial Infections
Table 52: Aminoglycoside Susceptibility of Strains Isolated from Hospitalized Patients with Pneumonia*
Table 53: Product Profile – Amikacin
Table 54: Efficacy of Amikacin in Patients with Bacterial Infections
Table 55: Safety of Amikacin in Patients with Bacterial Infections
Table 56: Product Profile – Gentamicin
Table 57: Efficacy of Gentamicin in Patients with Bacterial Infections
Table 58: Safety of Gentamicin in Patients with Bacterial Infections
Table 59: Product Profile – Tobramycin
Table 60: Product Profile – Tygacil
Table 61: Efficacy of Tygacil in Patients with cIAIs
Table 62: Efficacy of Tygacil in Patients with HAP/VAP
Table 63: Safety of Tygacil
Table64: Infrequently Used Antibiotics for the Treatment of HAI Caused by Gram-Negative Bacteria
Table 65: Key Late-Stage Pipeline Agents for HAIs Caused by Gram-Negative Bacteria, 2017
Table 66: Product Profile – Avibactam/Aztreonam
Table 67: Pathogen Susceptibility to Avibactam/Aztreonam
Table 68: Avibactam/Aztreonam SWOT Analysis, 2017
Table 69: Product Profile – Meropenem/Vaborbactam
Table 70: Meropenem/Vaborbactam – Phase III Clinical Trials
Table 71: Meropenem/Vaborbactam SWOT Analysis, 2017
Table 72: Product Profile – Relebactam/Imipenem/Cilastin
Table 73: Relebactam/Imipenem/Cilastin – Phase II and Phase III Clinical Trials
Table 74: Relebactam/Imipenem/Cilastin – Phase II Results (cIAI/cUTI)
Table 75: Safety of Relebactam/Imipenem/Cilastin
Table 76: Relebactam/Imipenem/Cilastin SWOT Analysis, 2017
Table 77: Product Profile – Cefiderocol
Table 78: Cefiderocol – Phase II and Phase III Clinical Trials
Table 79: Cefiderocol SWOT Analysis, 2017
Table 80: Product Profile – Eravacycline
Table 81: Eravacycline – Phase II and Phase III Clinical Trials
Table 82: Eravacycline – Phase III Clinical Trials Results for cIAIs
Table 83: Eravacycline – Safety Profile
Table 84: Eravacycline SWOT Analysis, 2017
Table 85: Product Profile – Finafloxacin
Table 86: Finafloxacin – Phase II Efficacy for Patients with UTI
Table 87: Finafloxacin SWOT Analysis, 2017
Table 88: Product Profile – Plazomicin
Table 89: Plazomicin – Clinical Trials
Table 90: Plazomicin – Results from Phase III Trial with cUTI Patients
Table 91: Plazomicin – Results from Phase III Trial with cUTI Patients
Table 92: Plazomicin – Safety Results from Phase III Trials
Table 93: Eravacycline SWOT Analysis, 2017
Table 94: Product Profile – Panobacumab
Table 95: Aerumab – Phase II Clinical Trials
Table 96: Aerumab – Phase II Clinical Trial Results
Table 97: Aerumab SWOT Analysis, 2017
Table 98: Product Profile – MEDI3902
Table 99: MEDI3902 – Phase II Clinical Trials
Table 100: MEDI3902 – Safety Data
Table 101: MEDI3902 SWOT Analysis, 2017
Table 102: Drugs in Development for HAI Caused by Gram-Negative Bacteria, 2017
Table 103: Key Companies in the HAIs Marketplace in the 7MM, 2017
Table 104: Pfizer’s HAI Portfolio Assessment, 2017
Table 105: Merck& Co’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 106: The Medicines Company’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 107: Shionogi’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 108: Tetraphase Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 109: MerLion Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 110: Achaogen’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 111: Aridis’ HAI Portfolio Assessment, 2017
Table 112: MedImmune’s Gram-Negative HAI Portfolio Assessment, 2017
Table 113: Allergan’s Gram-Negative HAI Portfolio Assessment, 2017
Table 114: Global (7MM) Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016–2026
Table 115: HAIs Caused by Gram-Negative Bacteria – Global Drivers and Barriers, 2016–2026
Table 116: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, 2016–2026
Table 117: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the US, 2016–2026
Table 118: HAIs caused by Gram-Negative Bacteria – US Drivers and Barriers, 2016–2026
Table 119: 5EU Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016–2026
Table 120: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the 5EU, 2016–2026
Table 121: HAIs Caused by Gram-Negative Bacteria – 5EU Drivers and Barriers, 2016–2026
Table 122: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, 2016–2026
Table 123: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in Japan, 2016–2026
Table 124: HAIs Caused by Gram-Negative Bacteria – Japan Drivers and Barriers, 2016–2026
Table 125: Key Historical and Projected Launch Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table 126: Projected Patent Expiry Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table 127: Key Assumptions for Avycaz
Table 128: Key Assumptions for Zerbaxa
Table 129: Key Assumptions for Piperacillin/tazobactam
Table 130: Key Assumptions for Ticarcillin/tazobactam
Table 131: Key Assumptions for Aztreonam
Table 132: Key Assumptions for Doribax
Table 133: Key Assumptions for Invanz
Table 134: Key Assumptions for Meropenem
Table 135: Key Assumptions for Imipenem
Table 136: Key Assumptions for Cefoxitin
Table 137: Key Assumptions for Cefotaxime
Table 138: Key Assumptions for Ceftriaxone
Table 139: Key Assumptions for Cefoperazone
Table 140: Key Assumptions for Ceftazidime
Table 141: Key Assumptions for Cefepime
Table 142: Key Assumptions for Zevtera
Table 143: Key Assumptions for Levofloxacin
Table 144: Key Assumptions for Ciprofloxacin
Table 145: Key Assumptions for Moxifloxacin
Table 146: Key Assumptions for Amikacin
Table 147: Key Assumptions for Gentamicin
Table 148: Key Assumptions for Tobramycin
Table 149: Key Assumptions for Polymyxin B
Table 150: Key Assumptions for Polymyxin E
Table 151: Key Assumptions for Tygacil
Table 152: Key Assumptions for Other Antibiotics
Table 153: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country